moderate - Elective orthopedic procedures (60-65% of revenue) are deferrable during economic downturns as patients delay non-urgent surgeries due to employment concerns, insurance coverage changes, or reduced discretionary healthcare spending. However, trauma and emergency procedures provide revenue stability. Hospital capital equipment budgets are procyclical, contracting during recessions when healthcare systems face margin pressure. Ambulatory surgical center growth, a key end-market, correlates with consumer confidence and employment levels since many procedures are cash-pay or high-deductible.

Rising interest rates create moderate headwinds through multiple channels: (1) higher borrowing costs for hospitals and ASCs reduce capital equipment budgets, (2) increased debt service costs on CONMED's $1.1B debt load (0.83 D/E ratio) compress net margins, (3) valuation multiple compression as medical device stocks typically trade on forward P/E and rising discount rates reduce present value of future earnings. However, CONMED's 11.4% FCF yield provides cushion. Lower rates are modestly positive by improving hospital financial flexibility and reducing CONMED's interest expense.

value - Trading at 1.0x P/S and 1.3x P/B with 11.4% FCF yield suggests deep value orientation despite operational challenges. The -31.8% one-year return and compressed margins attract contrarian investors betting on turnaround execution, margin recovery, or M&A potential. Not a growth stock given 5.2% revenue growth and mature market position. Dividend investors unlikely given need to prioritize debt reduction and reinvestment.